Ebrahim Variava to Anti-Retroviral Agents
This is a "connection" page, showing publications Ebrahim Variava has written about Anti-Retroviral Agents.
Connection Strength
0,443
-
Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children. N Engl J Med. 2021 12 30; 385(27):2531-2543.
Score: 0,141
-
HIV-1 antiretroviral drug resistance patterns in patients failing NNRTI-based treatment: results from a national survey in South Africa. J Antimicrob Chemother. 2017 01; 72(1):210-219.
Score: 0,098
-
Tuberculosis among adults starting antiretroviral therapy in South Africa: the need for routine case finding. Int J Tuberc Lung Dis. 2012 Sep; 16(9):1252-9.
Score: 0,073
-
Prolonged deferral of antiretroviral therapy in the SAPIT trial: did we need a clinical trial to tell us that this would increase mortality? S Afr Med J. 2010 Sep 07; 100(9):566, 568, 570-1.
Score: 0,065
-
Cohort profile: the potentially preventable burden of community-acquired pneumonia in South African adults in the era of widespread PCV13 immunisation and antiretroviral therapy roll-out, before and during the COVID-19 pandemic - the multicentre, multimethod PotPrev Study. BMJ Open. 2024 12 20; 14(12):e080553.
Score: 0,043
-
Epidemiology of severe acute respiratory illness (SARI) among adults and children aged =5 years in a high HIV-prevalence setting, 2009-2012. PLoS One. 2015; 10(2):e0117716.
Score: 0,022